Non-exclusive pharmaceutical rebate agreement for Ipratropiumbromid
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
No minimum quantities guaranteed; actual demand depends on many factors and may be very low.
Buyer may terminate the Open-House procedure early if exclusive rebate agreements are signed, ending all existing agree...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Supplies contract
- 1 lot
- Duration until Sep 2027
- Non-exclusive rebate agreements for pharmaceutical product Ipratropiumbromid (excluding dosage aerosol)
- Supply of medicines under rebate contract with AOK PLUS
Show full summary
Non-exclusive pharmaceutical rebate agreement for Ipratropiumbromid (ATC R03BB01) via an Open-House model. The buyer is AOK PLUS. No guaranteed volumes, no exclusivity, and the contract ends 30 September 2027. The notice is a transparency publication, not a formal procurement. Estimated value is not disclosed. Participation requires access to confidential documents via DTVP.
Risks
No minimum quantities guaranteed; actual demand depends on many factors and may be very low.
Buyer may terminate the Open-House procedure early if exclusive rebate agreements are signed, ending all existing agree...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur under §4 Abs.18 AMG regarding the offered medicines
- Must comply with EU sanctions against Russia (EU Reg. 833/2014)
Eligibility
- Must submit exclusion grounds declaration and Russia sanctions declaration
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
Erfurt, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-exclusive pharmaceutical rebate agreement for Ipratropiumbromid
Non-exclusive rebate agreements for Ipratropiumbromid (excluding dosage aerosol) under §130a SGB V. Open-House model with rolling admission until 30 Sept 2027.
Location
Duration
Category
Award Criteria
Deadline
Award details
Not applicable (Open-House model, no competitive award criteria)
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 09 Jul 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 478099-2026
Documents (1)
Similar tenders
Poland – Medical equipments, pharmaceuticals and personal care products – Dostawa materiałów medycznych jednorazowego użytku na potrzeby I Kliniki Chirurgii Ogólnej, Onkologicznej i Endokrynologicznej
Spain – Servers – Suministro de nuevo equipamiento informático para el CPD
Germany – Installation of doors and windows and related components – Tischlerarbeiten - Innentüren DIN 18355
Greece – Installation of cable laying – Προμήθεια υλικών και πλήρης κατασκευή της εναέριας Γ.Μ. 400kV ΚΥΤ ΝΕΑΣ ΣΑΝΤΑΣ – ΚΥΤ ΦΙΛΙΠΠΩΝ
Poland – Furniture – DZP.242.306.2026 Sukcesywny zakup wyposażenia meblowego wraz z dostawą, montażem i ustawieniem w pomieszczeniach Uniwersyteckiego Szpitala Klinicznego we Wrocławiu
Poland – Electricity, heating, solar and nuclear energy – Świecka Grupa Zakupowa. Dostawa energii elektrycznej w okresie od 01.01.2027r. do 31.12.2027r.
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
No minimum quantities guaranteed; actual demand depends on many factors and may be very low.
Buyer may terminate the Open-House procedure early if exclusive rebate agreements are signed, ending all existing agree...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications